Global X - Genomics & Biotechnology ETF (GNOM) Holdings

For informational purposes only. Not financial advice.

Quick Answer

Global X - Genomics & Biotechnology ETF (GNOM) has a last stored price of $72.30, as of the Oct 5, 2026 trading session. It has a 0.50% expense ratio and $47M in assets under management.

Holdings and weights below are as of Mar 15, 2026. In the stored portfolio snapshot, the largest listed holding is Moderna Inc (MRNA) at 7.86%, and the largest sector allocation is Healthcare at 99.7%.

Global X - Genomics & Biotechnology ETF (GNOM) ETF — Price, Holdings & Analysis

ETF Overview

GNOM aims to track the Solactive Genomics Index, focusing on companies that are expected to benefit from advancements in genomics and biotechnology. This includes firms involved in gene editing, DNA sequencing, and personalized medicine. The fund's strategy involves a concentrated portfolio of 49 holdings, allowing for targeted exposure to key players in the genomics revolution. GNOM's top holdings include Moderna Inc (7.86%), Praxis Precision Medicines Inc Ordinary Shares (6.23%), and Arrowhead Pharmaceuticals Inc (5.69%), reflecting a focus on companies at the forefront of genomic research and development. With a significant allocation to the healthcare sector (99.7%), GNOM provides investors with a specialized tool for participating in the growth of genomics and biotechnology. The remaining 0.3% is allocated to the technology sector. Past performance does not guarantee future results.

Risk Metrics

GNOM's concentrated portfolio of 49 holdings introduces concentration risk, as the performance of a few key companies can significantly impact the ETF's overall returns. The fund's heavy allocation to the healthcare sector (99.7%) exposes it to sector-specific risks, such as regulatory changes, clinical trial failures, and competition from other biotechnology companies. With a beta of 1.95, GNOM exhibits high volatility compared to the broader market, indicating that it may experience larger price swings. The expense ratio of 0.50% creates an expense drag on returns, which should be considered in the context of the fund's potential performance. Investors should carefully evaluate their risk tolerance and investment objectives before investing in GNOM. Past performance does not guarantee future results.

Beta: 1.95

Expense Ratio

0.50%

What does GNOM hold?

Holding	Weight
Moderna Inc (MRNA)	7.86%
Praxis Precision Medicines Inc Ordinary Shares (PRAX)	6.23%
Arrowhead Pharmaceuticals Inc (ARWR)	5.69%
Illumina Inc (ILMN)	5.13%
Guardant Health Inc (GH)	4.71%
Vertex Pharmaceuticals Inc (VRTX)	4.32%
BioMarin Pharmaceutical Inc (BMRN)	4.31%
Natera Inc (NTRA)	3.91%
BioNTech SE ADR (BNTX)	3.87%
Avidity Biosciences Inc Ordinary Shares (RNAM)	3.75%

Holdings and weights as of Mar 15, 2026. This fund data is more than 45 days old; verify current holdings with the issuer.

How Is the Fund Allocated?

Sector	Weight
Healthcare	99.7%
Technology	0.3%

Country	Weight
United States	83.3%
Netherlands	4.3%
Germany	3.6%
Switzerland	3.2%
United Kingdom	2.4%
Singapore	1.6%
China	1.6%
Other	0.0%

Dividend Yield

1.30%

ARK Innovation ETF (ARKK) — 0.75% expense ratio
Invesco QQQ Trust, Series 1 (QQQ) — 0.18% expense ratio
State Street SPDR Dow Jones Industrial Average ETF Trust (DIA) — 0.16% expense ratio
State Street Energy Select Sector SPDR ETF (XLE) — 0.08% expense ratio
State Street Technology Select Sector SPDR ETF (XLK) — 0.08% expense ratio
WisdomTree Emerging Markets ESG Fund (DVEM) — 0.32% expense ratio
Goldman Sachs ActiveBeta Emerging Markets Equity ETF (GEM) — 0.59% expense ratio
iShares MSCI EAFE ETF (EFA) — 0.32% expense ratio

Global X - MSCI Norway ETF (NORW) (Equity) — 0.50% expense ratio
Global X China Innovation ETF (KEJI) (Equity) — 0.75% expense ratio
Global X - MSCI SuperDividend EAFE ETF (EFAS) (Equity) — 0.55% expense ratio
Global X - Adaptive U.S. Risk Management ETF (ONOF) (Equity) — 0.39% expense ratio
Global X Funds - Global X Nasdaq 100 ESG Covered Call ETF (QYLE) (Equity) — 0.61% expense ratio
Global X - S&P 500 Catholic Values ETF (CATH) (Equity) — 0.29% expense ratio

Questions & Answers

What is GNOM and what does it track?

The Global X Genomics & Biotechnology ETF (GNOM) is an exchange-traded fund that seeks to replicate the price and yield performance of the Solactive Genomics Index.

This index is designed to track the performance of companies that are involved in the genomics and biotechnology industries.

What is the expense ratio for GNOM?

The expense ratio for the Global X Genomics & Biotechnology ETF (GNOM) is 0.50%. This means that for every $1000 invested in the fund, $5.00 is used to cover the fund's operating expenses.

While this is higher than some broad market ETFs, it is important to consider the specialized nature of the fund's investment strategy.

What are the top holdings in GNOM?

As of 2026-03-15, the top holdings in the Global X Genomics & Biotechnology ETF (GNOM) are concentrated in leading companies within the genomics and biotechnology industries.

The top three holdings are Moderna Inc (MRNA) at 7.86%, Praxis Precision Medicines Inc Ordinary Shares (PRAX) at 6.23%, and Arrowhead Pharmaceuticals Inc (ARWR) at 5.69%.

Is GNOM a good long-term investment?

Whether GNOM is a suitable long-term investment depends on an individual's investment goals, risk tolerance, and time horizon.

GNOM provides targeted exposure to the genomics and biotechnology sectors, which have the potential for long-term growth due to advancements in personalized medicine and gene editing. However, the fund's concentrated portfolio and sector-specific focus introduce risks that investors should carefully consider.

How does GNOM compare to similar ETFs?

GNOM differentiates itself through its specific focus on genomics and biotechnology companies. While other healthcare or biotechnology ETFs may offer broader exposure, GNOM provides a more targeted approach to investing in the genomics revolution.

GNOM has an expense ratio of 0.50% and an AUM of $0.05 billion.

Does GNOM pay dividends?

Yes, GNOM does pay dividends. As of 2026-03-15, the dividend yield for the Global X Genomics & Biotechnology ETF (GNOM) is 1.30%.

It's important to note that dividend yields can fluctuate based on market conditions and the performance of the underlying holdings.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

Written by machine, not reviewed page by page. Editorial oversight is systemic: the rules and the sources are checked, individual pages are not.